Furmonertinib plus anlotinib for EGFR-mutant lung cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two targeted therapy drugs (furmonertinib and anlotinib) for people with advanced lung adenocarcinoma that has spread to the brain and has an EGFR mutation. The goal is to see if this combination can shrink or control the brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have lung adenocarcinoma (a type of non-small cell lung cancer) that has spread to the brain.
- Your tumor has an EGFR mutation (a specific change in the cancer cells).
- You can have a brain scan (MRI or CT) that shows at least one brain tumor that can be measured.
- You have not had any previous cancer treatment for your advanced lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial compares two doses of the targeted drug furmonertinib (80 mg vs 160 mg) combined with chemotherapy for people with EGFR-mutated lung cancer that has spread to the brain. It aims to find out which dose works better and is safer.
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
Hear when a new Adenocarcinoma of Lung Metastatic to Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.